BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herrero JI, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F, Montiel C, Alegre F, Prieto J. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria: Expanded Criteria for LT in HCC. Liver Transpl 2008;14:272-8. [DOI: 10.1002/lt.21368] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Ashoori N, Bamberg F, Paprottka P, Rentsch M, Kolligs FT, Siegert S, Peporte A, Al-Tubaikh JA, D’Anastasi M, Hoffmann RT. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation. Digestion. 2012;86:338-348. [PMID: 23207185 DOI: 10.1159/000342813] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
2 Grat M, Kornasiewicz O, Hołówko W, Lewandowski Z, Zieniewicz K, Paczek L, Krawczyk M. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc 2013;45:1899-903. [PMID: 23769067 DOI: 10.1016/j.transproceed.2012.12.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
3 Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TL, Padia SA, Park JO, Riggle KM, Daoud SS. Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol 2015;7:1460-83. [PMID: 26085907 DOI: 10.4254/wjh.v7.i11.1460] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
4 Roayaie K, Roayaie S. Liver transplant for hepatocellular cancer: very small tumors, very large tumors, and waiting time. Clin Liver Dis. 2014;18:603-612. [PMID: 25017078 DOI: 10.1016/j.cld.2014.05.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, Minqing X, Jiaying Y. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore) 2014;93:e180. [PMID: 25474433 DOI: 10.1097/MD.0000000000000180] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
6 Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Burroughs AK. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl. 2011;17 Suppl 2:S58-S66. [PMID: 21584928 DOI: 10.1002/lt.22336] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
7 Gao T, Xia Q, Qiu DK, Feng YY, Chi JC, Wang SY, Xi ZF, Zhang JJ, Xu N, Chen SY. Comparison of survival and tumor recurrence rates in patients undergoing liver transplantation for hepatitis B-related hepatocellular carcinoma using Milan, Shanghai Fudan and Hangzhou criteria. J Dig Dis. 2013;14:552-558. [PMID: 23782458 DOI: 10.1111/1751-2980.12083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
8 Lee HW, Suh K. Advancements of liver transplantation for hepatocellular carcinoma in Korea. Japanese Journal of Clinical Oncology 2017;47:93-100. [DOI: 10.1093/jjco/hyw168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
9 Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1217-1226. [PMID: 20594247 DOI: 10.1111/j.1440-1746.2010.06335.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
10 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118. [PMID: 24945001 DOI: 10.1159/000343866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
11 D'Avola D, Iñarrairaegui M, Pardo F, Rotellar F, Marti P, Bilbao JI, Martinez-Cuesta A, Benito A, Alegre F, Mauleón E, Herrero JI, Quiroga J, Prieto J, Sangro B. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol 2011;18:1964-71. [PMID: 21267791 DOI: 10.1245/s10434-011-1551-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
12 Pinheiro RS, Waisberg DR, Nacif LS, Rocha-Santos V, Arantes RM, Ducatti L, Martino RB, Lai Q, Andraus W, D'Albuquerque LAC. Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? Transl Gastroenterol Hepatol 2017;2:68. [PMID: 28905009 DOI: 10.21037/tgh.2017.08.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
13 Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014;97 Suppl 8:S10-S17. [PMID: 24849822 DOI: 10.1097/01.tp.0000446267.19148.21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
14 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
15 Abreu P, Gorgen A, Griffiths C, Ivanics T, Sapisochin G. Downstaging and Expanded Criteria Hepatocellular Carcinoma Liver Transplantation. Curr Hepatology Rep 2019;18:400-7. [DOI: 10.1007/s11901-019-00492-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Decaens T, Roudot-Thoraval F, Badran H, Wolf P, Durand F, Adam R, Boillot O, Vanlemmens C, Gugenheim J, Dharancy S, Bernard PH, Boudjema K, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Hilleret MN, Chazouillères O, Cherqui D, Mallat A, Duvoux C. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver Int 2011;31:792-801. [PMID: 21645209 DOI: 10.1111/j.1478-3231.2010.02425.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
17 Nam JY, Lee JH, Bae J, Chang Y, Cho Y, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. Cancers (Basel) 2020;12:E2791. [PMID: 33003306 DOI: 10.3390/cancers12102791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22:309-18. [PMID: 27729631 DOI: 10.3350/cmh.2016.0042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
19 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018;24:3626-36. [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
20 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol. 2016;8:421-438. [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 16.2] [Reference Citation Analysis]
21 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
22 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 869] [Article Influence: 526.7] [Reference Citation Analysis]
23 Lu DS, Siripongsakun S, Kyong Lee J, Wei SH, Cheng PM, Sabounchi S, Lee JS, Raman S, Tong MJ, Busuttil RW, Sayre J. Complete tumor encapsulation on magnetic resonance imaging: A potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma: Complete Tumor Encapsulation. Liver Transpl 2013;19:283-91. [DOI: 10.1002/lt.23597] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ignacio Herrero J. III Reunión de consenso de la Sociedad Española de Trasplante Hepático (SETH). Hepatitis C, trasplante hepático de donante vivo, calidad de los injertos hepáticos y calidad de los programas de trasplante hepático. Gastroenterología y Hepatología 2011;34:641-59. [DOI: 10.1016/j.gastrohep.2011.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
25 Lei J, Wang W, Yan L. Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J Gastrointest Surg 2013;17:1752-9. [PMID: 23959694 DOI: 10.1007/s11605-013-2311-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
26 Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K, Krawczyk M. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 2014;38:2698-707. [PMID: 24858191 DOI: 10.1007/s00268-014-2647-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
27 Duvoux C, Roudot–thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard P, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux G, Chazouillères O, Salame E, Hilleret M, Lebray P, Abergel A, Debette–gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology 2012;143:986-994.e3. [DOI: 10.1053/j.gastro.2012.05.052] [Cited by in Crossref: 438] [Cited by in F6Publishing: 380] [Article Influence: 48.7] [Reference Citation Analysis]
28 Iñarrairaegui M, Pardo F, Bilbao J, Rotellar F, Benito A, D'avola D, Herrero J, Rodriguez M, Martí P, Zozaya G, Dominguez I, Quiroga J, Sangro B. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2012;38:594-601. [DOI: 10.1016/j.ejso.2012.02.189] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 7.8] [Reference Citation Analysis]
29 Guiteau JJ, Cotton RT, Washburn WK, Harper A, O’Mahony CA, Sebastian A, Cheng S, Klintmalm G, Ghobrial M, Halff G. An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant. 2010;10:2092-2098. [PMID: 20883543 DOI: 10.1111/j.1600-6143.2010.03222.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
30 Rhu J, Kim JM, Choi GS, Kwon CHD, Joh JW. Validation of the α-fetoprotein Model for Hepatocellular Carcinoma Recurrence After Transplantation in an Asian Population. Transplantation 2018;102:1316-22. [PMID: 29470357 DOI: 10.1097/TP.0000000000002136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
31 Massoumi H, Elsiesy H, Khaitova V, Peterson B, Norkus E, Grewal P, Liu L, Chang C, Bach N, Schiano TD. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation. 2009;88:729-735. [PMID: 19741473 DOI: 10.1097/tp.0b013e3181b2e0d1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S277-S282. [PMID: 15508095 DOI: 10.1007/978-1-60327-376-3_19] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Hibi T, Itano O, Shinoda M, Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today 2017;47:403-15. [PMID: 27130463 DOI: 10.1007/s00595-016-1337-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
34 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
35 Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Current Opinion in Organ Transplantation 2016;21:91-8. [DOI: 10.1097/mot.0000000000000282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
36 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Kashkoush S, El Moghazy W, Kawahara T, Gala-lopez B, Toso C, Kneteman NM. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant 2014;28:728-36. [DOI: 10.1111/ctr.12373] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
38 Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552-559. [PMID: 27899297 DOI: 10.1016/j.jhep.2016.10.038] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
39 Federico P, Petrillo A, Giordano P, Bosso D, Fabbrocini A, Ottaviano M, Rosanova M, Silvestri A, Tufo A, Cozzolino A, Daniele B. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers (Basel) 2020;12:E3025. [PMID: 33080958 DOI: 10.3390/cancers12103025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
40 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
41 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 16.0] [Reference Citation Analysis]
42 Andreou A, Gül S, Pascher A, Schöning W, Al-Abadi H, Bahra M, Klein F, Denecke T, Strücker B, Puhl G. Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma. HPB (Oxford). 2015;17:168-175. [PMID: 25263399 DOI: 10.1111/hpb.12345] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
43 Romano F, Stroppa P, Bravi M, Casotti V, Lucianetti A, Guizzetti M, Sonzogni A, Colledan M, D’Antiga L. Favorable outcome of primary liver transplantation in children with cirrhosis and hepatocellular carcinoma. Pediatr Transplant. 2011;15:573-579. [PMID: 21797955 DOI: 10.1111/j.1399-3046.2011.01528.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
44 Slotta JE, Kollmar O, Ellenrieder V, Ghadimi BM, Homayounfar K. Hepatocellular carcinoma: Surgeon’s view on latest findings and future perspectives. World J Hepatol. 2015;7:1168-1183. [PMID: 26019733 DOI: 10.4254/wjh.v7.i9.1168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
45 Shindoh J, Hashimoto M, Watanabe G. Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol. 2015;7:70-77. [PMID: 25624998 DOI: 10.4254/wjh.v7.i1.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
46 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
47 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1579] [Article Influence: 321.3] [Reference Citation Analysis]
48 Decaens T, Hurtova M, Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire. Gastroentérologie Clinique et Biologique 2009;33:61-9. [DOI: 10.1016/j.gcb.2008.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant. 2016;21:231-237. [PMID: 26918880 DOI: 10.1097/mot.0000000000000294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
50 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
51 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
52 Donat M, Alonso S, Pereira F, Ferrero E, Carrión L, Acin-Gándara D, Moreno E. Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation. Transplant Proc 2016;48:1968-77. [PMID: 27569930 DOI: 10.1016/j.transproceed.2016.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
53 Hurtova M, Decaens T, Laurent A, Cherqui D, Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire et chez les malades avec antécédents de cancer. La Presse Médicale 2009;38:1272-80. [DOI: 10.1016/j.lpm.2009.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, Zhu HB, Zhang Q, Chen GH. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One 2011;6:e25295. [PMID: 21966488 DOI: 10.1371/journal.pone.0025295] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
55 De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, Cooper A, Esquivel C, Nguyen MH. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant. 2009;9:1158-1168. [PMID: 19344435 DOI: 10.1111/j.1600-6143.2009.02576.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 7.7] [Reference Citation Analysis]
56 Maggs JRL, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1113-34. [DOI: 10.1111/j.1365-2036.2012.05072.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
57 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 188] [Article Influence: 40.3] [Reference Citation Analysis]
58 Civan JM. Liver Transplantation for HCC: The Milan Criteria. In: Doria C, editor. Contemporary Liver Transplantation. Cham: Springer International Publishing; 2016. pp. 1-19. [DOI: 10.1007/978-3-319-05543-5_11-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
59 Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-S57. [PMID: 21695773 DOI: 10.1002/lt.22365] [Cited by in Crossref: 320] [Cited by in F6Publishing: 279] [Article Influence: 35.6] [Reference Citation Analysis]
60 Suh KS, Lee HW. Liver transplantation for advanced hepatocellular carcinoma: how far can we go? Hepat Oncol 2015;2:19-28. [PMID: 30190984 DOI: 10.2217/hep.14.34] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
61 Tanaka K. Resection versus transplantation for hepatocellular carcinoma exceeding Milan criteria within increasing donor shortage. Hepatobiliary Surg Nutr 2017;6:280-3. [PMID: 28848755 DOI: 10.21037/hbsn.2017.03.14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Fortune BE, Umman V, Gilliland T, Emre S. Liver transplantation for hepatocellular carcinoma: a surgical perspective. J Clin Gastroenterol 2013;47 Suppl:S37-42. [PMID: 23632344 DOI: 10.1097/MCG.0b013e318286ff8e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
63 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Lei JY, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol. 2013;19:6077-6083. [PMID: 24106409 DOI: 10.3748/wjg.v19.i36.6077] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
65 Hemming AW, Berumen J, Mekeel K. Hepatitis B and Hepatocellular Carcinoma. Clin Liver Dis. 2016;20:703-720. [PMID: 27742009 DOI: 10.1016/j.cld.2016.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
66 Sempokuya T, Wong LL. Ten-year survival and recurrence of hepatocellular cancer. Hepatoma Res 2019;5:38. [PMID: 31701016 DOI: 10.20517/2394-5079.2019.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Feng K, Ma KS. Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol 2014;20:5987-98. [PMID: 24876721 DOI: 10.3748/wjg.v20.i20.5987] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
68 Pfiffer TE, Seehofer D, Nicolaou A, Neuhaus R, Riess H, Trappe RU. Recurrent hepatocellular carcinoma in liver transplant recipients: Parameters affecting time to recurrence, treatment options and survival in the sorafenib era. Tumori 2011;97:436-41. [DOI: 10.1177/030089161109700404] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
69 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 14.2] [Reference Citation Analysis]
70 Zhu Z. Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:498-502. [PMID: 28124007 DOI: 10.21037/hbsn.2016.12.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
72 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. WJCO 2021;12:623-45. [DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
73 Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:423-32. [DOI: 10.1038/nrgastro.2009.86] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 6.7] [Reference Citation Analysis]
74 . III Reunión de consenso de la Sociedad Española de Trasplante Hepático (SETH). Hepatitis C, trasplante hepático de donante vivo, calidad de los injertos hepáticos y calidad de los programas de trasplante hepático. Cirugía Española 2011;89:487-504. [DOI: 10.1016/j.ciresp.2011.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
75 Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 2011;17 Suppl 2:S81-S89. [PMID: 21748847 DOI: 10.1002/lt.22380] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
76 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
77 Piros L, Fehérvári I, Görög D, Nemes B, Szabó J, Gerlei Z, Végső G, Kóbori L, Máthé Z. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest. Transplantation Proceedings 2015;47:2201-6. [DOI: 10.1016/j.transproceed.2015.07.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
78 Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int 2009;22:869-75. [PMID: 19386075 DOI: 10.1111/j.1432-2277.2009.00882.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
79 Akbulut S, Koc C. Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation? J Gastrointest Cancer 2020;51:1107-13. [PMID: 32857265 DOI: 10.1007/s12029-020-00482-0] [Reference Citation Analysis]
80 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35 Suppl 1:129-138. [PMID: 25529098 DOI: 10.1111/liv.12713] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
81 Lei J, Zhong J, Luo Y, Yan L, Zhu J, Wang W, Li B, Wen T, Yang J; Liver Surgery Group. Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation. Oncotarget 2017;8:91328-42. [PMID: 29207647 DOI: 10.18632/oncotarget.20511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
82 Sapisochin G, Rodríguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J, Castroagudín JF, Varo E, López-andujar R, Palacios F, Sanchez Antolín G, Perez B, Guiberteau A, Blanco G, González-diéguez ML, Rodriguez M, Varona MA, Barrera MA, Fundora Y, Ferron JA, Ramos E, Fabregat J, Ciria R, Rufian S, Otero A, Vazquez MA, Pons JA, Parrilla P, Zozaya G, Herrero JI, Charco R, Bruix J. “ Very Early ” Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients?: “ Very Early ” Intrahepatic Cholangiocarcinoma. American Journal of Transplantation 2014;14:660-7. [DOI: 10.1111/ajt.12591] [Cited by in Crossref: 86] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
83 Gundlach JP, Schmidt S, Bernsmeier A, Günther R, Kataev V, Trentmann J, Schäfer JP, Röcken C, Becker T, Braun F. Indication of Liver Transplantation for Hepatocellular Carcinoma Should Be Reconsidered in Case of Microvascular Invasion and Multilocular Tumor Occurrence. J Clin Med 2021;10:1155. [PMID: 33801887 DOI: 10.3390/jcm10061155] [Reference Citation Analysis]
84 Wang Z, Song S, Teng F, Wang G, Guo W, Shi X, Ma J, Wu Y, Ding G, Fu Z. A single-center retrospective analysis of liver transplantation on 255 patients with hepatocellular carcinoma: A single-center retrospective analysis. Clinical Transplantation 2010;24:752-7. [DOI: 10.1111/j.1399-0012.2009.01172.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
85 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
86 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52:930-936. [PMID: 20385428 DOI: 10.1016/j.jhep.2009.12.032] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 8.0] [Reference Citation Analysis]
88 Jiang L, Lei JY, Wang WT, Yan LN, Li B, Wen TF, Xu MQ, Yang JY, Wei YG. Immediate Radical Therapy or Conservative Treatments When Meeting the Milan Criteria for Advanced HCC Patients After Successful TACE. J Gastrointest Surg 2014;18:1125-30. [DOI: 10.1007/s11605-014-2508-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]